An interventional study of Fast + High-fat low-carbohydrate diet and Fast + Empagliflozin in Myocardial Suppression, sponsored by Matthieu Pelletier-Galarneau, MD MSc. Completed at 1 site in Canada. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-29.
Sponsored by Matthieu Pelletier-Galarneau, MD MSc · Not applicable, Interventional, and Diagnostic
The overall objective of this study is to assess if the empagliflozin has the potential to substitute the high fat low carb (HFLC) diet for the preparation of cardiovascular FDG-PET studies.
The overall objective of this study is to assess if the SGLT2 inhibitor empagliflozin has the potential to substitute the high fat low carb (HFLC) diet for the preparation of cardiovascular FDG-PET studies. This study will evaluate if an acute administration of empagliflozin (tablets of 10 and/or 25 mg) combined with fasting can sufficiently increase the BHB levels, a proxy of myocardial FDG uptake.
Matthieu Pelletier-Galarneau, MD MSc is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants will be instructed to follow a strict HFLC diet starting on the morning of the day before the visit and to fast for 14 hours, starting at 7pm the day before the visit. Participants will be allowed to drink water and take their medications.
Participants will be instructed to fast for 14 hours, starting at 7pm the day before the visit. Participants will be allowed to drink water and take their medications. Participants will also be instructed to take an oral dose of 50 mg of empagliflozin at 7am the morning before the experimental visit and on the day of the experimental visit.
Levels of serum Beta-hydroxybutyrate (BHB) mmol/L
Average differences in serum levels of BHB measured following a fast and administration of empagliflozin versus following a fast preceded by a HFLC diet
Time frame: 1 day
Proportions of serum Beta-hydroxybutyrate (BHB) >0.5 mmol/L
Proportion of participants with serum BHB \>0.5 mmol/L following a fast and administration of empagliflozin versus following a fast preceded by a HFLC diet.
Time frame: 1 day
Proportions of glycemia levels (mmol/L) <3.5 mmol/L
Proportion of participants with glycemia \<3.5 mmol/L following a fast and administration of empagliflozin versus following a fast preceded by a HFLC diet.
Time frame: 1 day
Acceptability and tolerance of each protocol, as reported by patients by a dedicated survey.
Proportion of participants who preferred the empagliflozin to the HFLC diet as assessed by a dedicated survey.
Time frame: Through study completion, up to 3 months.
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Matthieu Pelletier-Galarneau, MD MSc